ARRY-382
ARRY-382 is a potent, oral and highly selective inhibitor of CSF1R/c-Fms with an IC50 of 9 nM. ARRY-382 can be used for the research of advanced or metastatic cancers[1].
Product Specifications
CAS Number
1313407-95-2
UNSPSC
12352005
Target
C-Fms
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/c-fms-in-12.html
Purity
99.95
Solubility
DMSO : 8.33 mg/mL (ultrasonic)
Smiles
O=C(C1=CN=C2C=C(OCCN3CCN(C)CC3)C=CN21)NC4=CC=CC5=C4C(C6CC6)=NN5CC7=NC(C)=CC=C7
Molecular Formula
C32H36N8O2
Molecular Weight
564.68
References & Citations
[1]David K Edwards V, et al. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget. 2018 May 15;9 (37) :24576-24589.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400155-100 1x 100 µL
CD19 (CVID3/155), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
